// App-Quantinova.ai

1495 : Pharmacokinetics-Based Modification of Intravenous Pegylated Asparaginase Dosing in the Context of a Pediatric-inspired Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Dan Douer

Principal Investigators

  • Ibrahim Aldoss

  • Matthew A Lunning

  • Laleh Ramezani

  • Patrick Burke

  • Lisa Mark

  • Janice Vrona

  • Jae H. Park

  • Martin S Tallman

  • Vinod Pullarkat

  • Ann M Mohrbacher

  • Vassilos I Avramis

Medical Centers

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Acute lymphoblastic leukemia

  • Hyperglycemia

  • Pancreatitis

  • Anaphylaxis

  • Venous thrombosis

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Hydrocortisone

  • Pegaspargase

  • Oncaspar

  • Asparaginase

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved